Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.

We propose a mathematical model to interpret observations concerning the behavior of broadly neutralizing antibodies for chronic HIV in vivo. The model enables us to identify a threshold antibody level that must be achieved to decrease the viral load effectively. Although this threshold has not been reached in existing passive immunization studies, it is within range of humoral immune responses, suggesting that therapeutic vaccines are feasible. In an appendix, we develop a model of passive immunization against influenza, and acute infection.

[1]  H. Katinger,et al.  Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. , 2004, The Journal of antimicrobial chemotherapy.

[2]  Lei Zhang,et al.  Understanding the mechanisms and limitations of immune control of HIV , 2007, Immunological reviews.

[3]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[4]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[5]  A. Trkola,et al.  In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10 , 2007, Journal of Virology.

[6]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[7]  Abner Louis Notkins,et al.  Half-life of polyreactive antibodies , 1994, Journal of Clinical Immunology.

[8]  H. Liao,et al.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.

[9]  N. Kolaitis,et al.  Polyreactive igm antibodies in the circulation are masked by antigen binding , 1994, Journal of Clinical Immunology.

[10]  A. Perelson,et al.  Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination , 2004, Journal of Virology.

[11]  Stanca M. Ciupe,et al.  Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. , 2011, Journal of theoretical biology.

[12]  Pojen P. Chen,et al.  The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.

[13]  A. Perelson,et al.  Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.

[14]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[16]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[17]  Simon Wain-Hobson.  Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.

[18]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[19]  D M Bortz,et al.  Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models. , 2006, Mathematical biosciences.

[20]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[21]  José A Fernández,et al.  Cardiolipin is a normal component of human plasma lipoproteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[23]  Alan S Perelson,et al.  HIV-1 infection and low steady state viral loads , 2002, Bulletin of mathematical biology.

[24]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[25]  A S Perelson,et al.  Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. , 1996, Journal of theoretical biology.